Back to News
Market Impact: 0.25
First patient treated with Leqembi® (lecanemab) in Sweden
Source: PR Newswire
Healthcare & BiotechProduct Launches
BioArctic announced that Leqembi is now available at a private clinic in Sweden, with the first Swedish patient beginning treatment outside of a clinical-trial setting. The milestone expands real-world access to the Alzheimer's therapy in BioArctic's home market, though the announcement provides no revenue, pricing, or patient-volume details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
BIOA.B0.65
More News
- Trump Says US Team Met With Iranians at UNGA
- Meta’s Muse AI is exploding in popularity—and already drawing heated backlash from another tech giant
- Qualcomm releases Android chip built for AI as memory shortage weighs on smartphone market
- Alibaba says it built the ‘most powerful AI chip in China’ as the country races to catch up with the U.S.
- Alibaba says its new Zhenwu V900 is China’s most powerful AI chip
- Alibaba shares jump as new AI chip, data center buildout plans unveiled
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Bitcoin's 52% Crash Proves It's a Tech Stock: Here's What That Means for Portfolio Construction
- What Is an AI Investment Research Platform?